Core Insights - LPL Financial and Simplicity Group have formed a strategic relationship to enhance insurance capabilities and support for LPL advisors, effective May 1, 2026 [1] - Simplicity will serve as LPL's preferred Brokerage General Agency, providing advanced technology and comprehensive insurance resources [1] - The partnership aims to improve service experiences for clients seeking protection solutions and offers a broad suite of offerings for high-net-worth clients [1] Company Overview - LPL Financial is a leading wealth management firm supporting over 32,000 financial advisors and approximately 1,200 financial institutions, managing around $2.4 trillion in brokerage and advisory assets for about 8 million Americans [1] - Simplicity Group is recognized as a leading partner for advisors and financial institutions, focusing on wealth accumulation and financial protection products [1] Strategic Benefits - The agreement allows LPL to transition its internal insurance business to Simplicity, creating a unified experience for advisors and clients [1] - This strategic shift enables LPL to reinvest in delivering greater value, flexibility, and improved features for advisors and institutions [1]

Levi & Korsinsky Reminds Paysafe Limited Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2026 - PSFE [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Paysafe Limited ("Paysafe Limited" or the "Company") (NYSE: PSFE) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Paysafe Limited investors who were adversely affected by alleged securities ...

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Picard Medical, Inc.(PMI) Shareholders [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Picard Medical, Inc. ("Picard Medical, Inc." or the "Company") (NYSE: PMI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Picard Medical, Inc. investors who were adversely affected by alleged securities fraud be ...

Klarna Group plc Class Action: Levi & Korsinsky Reminds Klarna Group plc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 20, 2026 - KLAR [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Klarna Group plc ("Klarna Group plc" or the "Company") (NYSE: KLAR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Klarna Group plc investors who were a ...

Fermi Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 6, 2026 to Discuss Your Rights - FRMI [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fermi Inc. ("Fermi Inc." or the "Company") (NASDAQ: FRMI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fermi Inc. investors who were adversely affected by alleged securities fraud. This lawsuit ...

Core Insights - ICON plc is under investigation following an internal accounting probe that revealed potential revenue overstatements for fiscal years 2023 and 2024, estimated at up to 2% each year [1] - The company has delayed the release of its fourth-quarter and full-year 2025 financial results due to this investigation [1] Company Overview - ICON plc is one of the largest contract research organizations (CROs) globally, providing outsourced drug development and clinical trial management services to pharmaceutical and biotechnology companies [1] - The CRO industry relies on long-term service contracts, making accurate revenue recognition critical [1] Financial Impact - An overstatement of up to 2% on annual revenue, given ICON's reported full-year revenue exceeding $8 billion, could represent a discrepancy of approximately $160 million per year [1] - This discrepancy could materially affect earnings per share, operating margins, and year-over-year growth rates [1] Recent Financial Performance - In the third quarter of 2025, the company reported revenue of $2.043 billion, reflecting a year-on-year increase of 0.6% [1] - The previous year's comparison figures for this growth claim are now under review due to the ongoing investigation [1] Market Reaction - Following the February 12, 2026 disclosure, ICON plc's shares declined approximately 40%, resulting in the loss of billions in market capitalization [1] - The company had repurchased $750 million of its own shares in the first three quarters of 2025 and authorized an additional $1 billion repurchase program in the second quarter, which was presented against a backdrop of a "very strong" financial position [1]

Core Viewpoint - A class action securities lawsuit has been filed against agilon health, inc. (AGL) for alleged securities fraud affecting investors between February 26, 2025, and August 4, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements and concealed information regarding the company's 2025 guidance, which was deemed unachievable due to known industry challenges [1] - It is alleged that defendants overstated the financial benefits from strategic actions taken by agilon to mitigate risks, leading to materially false and misleading statements about the company's business and prospects [1] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until March 2, 2026, to request appointment as lead plaintiff, with no costs or obligations to participate in the lawsuit [1] - Levi & Korsinsky, LLP, the law firm handling the case, has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [1]

Core Insights - Medpace Holdings, Inc. is under investigation for potential securities law claims due to discrepancies between public statements and internal data regarding its clinical-trial booking pipeline [1] - The company reported a Q4 2025 book-to-bill ratio of 1.04, significantly lower than its historical range of 1.10 to 1.25, indicating a concerning trend in business health [1] - Following the earnings report, Medpace shares dropped approximately 15.9%, primarily attributed to the bookings miss [1] Company Performance - Medpace reported Q4 2025 revenue of $708.5 million and GAAP EPS of $4.67, both exceeding consensus estimates [1] - The ending backlog as of December 31, 2025, was approximately $3 billion, reflecting a modest year-over-year growth of 4.3% [1] Industry Context - The book-to-bill ratio is a critical forward-looking indicator in the contract research organization (CRO) sector, with significant implications for valuation and investor expectations [1] - The CRO industry experienced record demand post-pandemic, making any decline in booking momentum particularly impactful for investor assessments of future growth [1]

Oracle Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 6, 2026 to Discuss Your Rights - ORCL [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Oracle Corporation ("Oracle" or the "Company") (NYSE: ORCL) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Oracle investors who were adversely affected by alleged securities fraud between June 12, 2 ...

Core Insights - Unisys will participate as a gold sponsor in the 2026 Cybersecurity Summit, focusing on strategies for operational resilience and risk reduction in cybersecurity [1] - Philip Swarbrick, Unisys's VP of cybersecurity solutions, will discuss the impact of AI on threat detection and risk management during the panel session titled "AI and Emerging Tech at the 2026 Security Frontline" [1] - Research from Unisys indicates that fewer than 15% of organizations are adopting a proactive cybersecurity approach, highlighting the need for stronger defenses against emerging threats [1] Event Details - The Cybersecurity Summit will take place on February 25, 2026, at the Sheraton New York Times Square Hotel, with the panel discussion scheduled for 11:30 a.m. EST [1] - The session will address how AI is reshaping risk mitigation and the challenges posed by generative systems and data integrity [1] Industry Context - The cybersecurity landscape is evolving, with increasing risks such as data privacy breaches and social engineering, necessitating collaboration within the industry to enhance defenses [1] - Unisys emphasizes the importance of adopting robust cybersecurity measures to address sophisticated challenges introduced by AI technologies [1]